Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-03-06Clinical Trial Update: Local Anesthetic Treatments for Overactive Bladder [Phase 3]
Phase 3 trial update for local anesthetic treatments in overactive bladder; trial terminated with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-03-02Clinical Trial Update: A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) [Phase 2]
A Phase 2 trial evaluating once-daily low and high dose solabegron versus placebo for 12 weeks in women with overactive bladder has complete…
-
CLINICAL_TRIALS trial_result · 2020-03-02Clinical Trial Update: Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women [Phase 2]
Phase 2 trial evaluating the efficacy and safety of solabegron tablets in adult women with overactive bladder has completed.
-
FDA approval · 2020-02-28FDA Approved: OXYBUTYNIN CHLORIDE EXTENDED RELEASE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for an extended-release formulation of oxybutynin chloride, manufactured by Rising Pharma Holdings, …
-
FDA approval · 2020-02-28FDA Approved: OXYBUTYNIN — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for the generic oxybutynin product developed by Zydus Pharmaceuticals USA Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-02-28FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved a supplemental application for oxybutynin chloride from Ajanta Pharma USA Inc., authorizing the generic oxybutynin chloride pro…
-
CLINICAL_TRIALS trial_result · 2020-02-26Clinical Trial Update: Foot/Hand Neuromodulation for Overactive Bladder (OAB) [NA]
A terminated clinical trial investigating foot/hand neuromodulation for overactive bladder with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-02-19Clinical Trial Update: A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment [Phase 2]
Phase 2 trial investigating the effects of fesoterodine and oxybutynin on cognitive function in individuals with mild cognitive impairment a…
-
CLINICAL_TRIALS trial_result · 2020-02-07Clinical Trial Update: A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder [Phase 2]
Phase 2 exploratory trial of DA-8010 in patients with overactive bladder has been completed.
-
FDA approval · 2020-01-24FDA Approved: TOLTERODINE TARTRATE — Original Application (Rising Pharma Holdings, Inc.)
FDA approved Tolterodine Tartrate under an original application for generic use by Rising Pharma Holdings, Inc., for the treatment of overac…
-
FDA approval · 2020-01-06FDA Approved: DARIFENACIN — Original Application (POLYGEN PHARMACEUTICALS INC.)
The FDA approved the original generic application for darifenacin hydrobromide, a generic version of darifenacin for overactive bladder.
-
CLINICAL_TRIALS trial_result · 2020-01-03Clinical Trial Update: Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home [NA]
A completed clinical trial evaluating posterior tibial nerve stimulation for overactive bladder; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2019-12-24Clinical Trial Update: Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence [Phase 4]
Phase 4 trial evaluating an alternative injection paradigm for onabotulinumtoxinA (BOTOX) in overactive bladder with urinary incontinence ha…
-
CLINICAL_TRIALS trial_result · 2019-12-11Clinical Trial Update: Fall Prevention in Older Adults With OAB [Phase 4]
Phase 4 clinical trial evaluating fall prevention in older adults with overactive bladder has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-12-02Clinical Trial Update: Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients [Phase 4]
Phase 4 trial update exploring predictors of symptom relapse after discontinuation of treatment in overactive bladder patients.
-
CLINICAL_TRIALS trial_result · 2019-12-02Clinical Trial Update: Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) [Phase 4]
A Phase 4 trial comparing doxazosin plus tolterodine SR 2 mg vs 4 mg in men with overactive bladder and benign prostatic hyperplasia to asse…
-
CLINICAL_TRIALS trial_result · 2019-10-23Clinical Trial Update: A Trial of Transcutaneous Nerve Stimulation for OAB [NA]
Completed clinical trial evaluating transcutaneous nerve stimulation for overactive bladder; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-10-02Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) [Phase 4]
Phase 4 trial evaluating mirabegron for overactive bladder symptoms in men taking tamsulosin for lower urinary tract symptoms due to benign …
-
CLINICAL_TRIALS trial_result · 2019-09-26Clinical Trial Update: Fesoterodine on Urgency Episodes in Parkinson's Disease Population [Phase 4]
Phase 4 trial update on fesoterodine for urgency episodes in Parkinson's disease; study terminated.
-
FDA approval · 2019-09-23FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Accord Healthcare, Inc.)
FDA approved a supplemental application for oxybutynin chloride from Accord Healthcare, indicating approval of changes to the product under …
-
FDA approval · 2019-09-23FDA Approved: SOLIFENACIN SUCCINATE — Supplemental Application (Novadoz Pharmaceuticals LLC)
The FDA approved a supplemental application for solifenacin succinate submitted by Novadoz Pharmaceuticals LLC.
-
FDA approval · 2019-09-09FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for oxybutynin chloride submitted by Chartwell RX, LLC. The approval confirms continuation of the ge…
-
FDA approval · 2019-08-27FDA Approved: SOLIFENACIN SUCCINATE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approves Unichem's original application for solifenacin succinate as a generic, enabling a generic version of the drug for overactive bl…
-
FDA approval · 2019-08-19FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for oxybutynin chloride from Amneal Pharmaceuticals LLC.
-
FDA approval · 2019-08-19FDA Approved: OXYBUTYNIN — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for oxybutynin submitted by Zydus Pharmaceuticals USA Inc.